Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + pegylated liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
everolimus + pegylated liposomal doxorubicin is a combination therapy investigated for the treatment of advanced solid tumors. Everolimus (RAD001) is a small molecule inhibitor of the mammalian target of rapamycin (mTOR), specifically the mTORC1 complex, which plays a central role in regulating cell growth, proliferation, and survival. Pegylated liposomal doxorubicin (Caelyx) is a formulation of the anthracycline doxorubicin encapsulated in liposomes, which improves its pharmacokinetic profile and reduces cardiotoxicity. Doxorubicin acts by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage and apoptosis. This combination was evaluated in a Phase 1 dose-finding study conducted by the Southern Europe New Drug Organization (SENDO) to establish the safety, tolerability, and recommended dose in patients with advanced malignancies.
- Brand names
- CaelyxAfinitorZortress
- Other names
- RAD001 + CaelyxEverolimus + PLDpegylated liposomal doxorubicinPLD
02
Targets
mTOR (Mammalian target of rapamycin kinase)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on everolimus + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + pegylated liposomal doxorubicin.